Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01AKK
|
|||
| Former ID |
DIB013160
|
|||
| Drug Name |
ALXN1101
|
|||
| Indication | Molybdenum cofactor deficiency [ICD-11: 5B5K.A; ICD-10: E61.5] | Phase 2/3 | [1] | |
| Company |
Alexion pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic pyranopterin monophosphate synthase (MOCS1) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.